查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1961256

甲狀腺疾病治療市場－全球產業規模、佔有率、趨勢、機會、預測：按適應症、給藥途徑、分銷管道、地區和競爭格局分類，2021-2031年

Thyroid Gland Disorder Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication, By Route of Administration, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球甲狀腺疾病治療市場預計將從 2025 年的 29.3 億美元成長到 2031 年的 37.7 億美元，複合年成長率為 4.29%。

該市場涵蓋多種藥物干預和治療方法，例如左旋甲狀腺素和放射性碘，用於恢復甲狀腺機能低下症以及人口老化加劇，導致長期疾病管理需求增加。例如，美國癌症協會估計，到2025年，美國將新增約44,020例甲狀腺癌病例。如此龐大的患者群體凸顯了穩定可靠的治療方案供應的迫切需求，並刺激了國際醫療保健系統對有效治療方案的需求。

市場概覽
預測期 2027-2031
市場規模：2025年 29.3億美元
市場規模：2031年 37.7億美元
複合年成長率：2026-2031年 4.29%
成長最快的細分市場 口服
最大的市場 北美洲

然而，由於新治療方法核准的嚴格監管框架，該領域面臨許多重大障礙。嚴格的合規要求和全面的安全檢驗往往會延緩新藥的研發進程並增加營運成本。這些監管障礙有效地減緩了創新治療方法進入商業市場的速度，並可能阻礙其在醫療基礎設施尚未完善的新興經濟體中的推廣。

市場促進因素

全球甲狀腺疾病盛行率的不斷上升是市場成長的主要驅動力，也因此對荷爾蒙補充療法的穩定供應產生了迫切需求。隨著人口老化和診斷能力的提高，甲狀腺機能低下症減退症的發生率不斷上升，人們對左旋甲狀腺素等標準療法的依賴性也日益增強。這種持續的患者需求為成熟的製藥公司帶來了顯著的商業性規模，確保了其在慢性病治療領域的穩定收入。例如，根據默克集團2025年11月發布的報告，其旗艦甲狀腺藥物Eucilox在全球強勁需求的支撐下，實現了9.6%的有機淨銷售額成長。此外，美國食品藥物管理局（FDA）2025年8月發布的新聞稿指出，2024年美國約有2,200萬名患者服用左旋甲狀腺素，這進一步凸顯了該疾病的沉重負擔。

同時，新藥製劑的推出正在拓展傳統非專利荷爾蒙補充療法以外的收入來源。製藥公司正大力投資生物製藥和標靶治療，以應對甲狀腺眼疾（TED）和難治性甲狀腺癌等複雜疾病。這些創新治療方法為傳統療法提供了高價值的替代方案，並透過卓越的臨床療效和溢價不斷擴大市場佔有率。安進公司在2025年第三季財報中揭露，其用於治療甲狀腺眼疾的標靶治療Tepeza的全球銷售額年增15%，達5.6億美元。這種成長標誌著產業正朝著針對甲狀腺疾病領域特定未滿足需求的專科療法方向發生重大轉變。

市場挑戰

嚴格的法規結構對全球甲狀腺疾病治療市場的成長構成重大阻礙。研發公司必須遵守複雜的合規程序，並進行全面的臨床試驗以驗證新治療方法的安全性和有效性。這些嚴格的要求顯著增加了營運成本，延長了研發週期，造成了瓶頸，延緩了創新藥物的商業化。因此，市場無法快速回應醫療服務提供者和患者不斷變化的需求，導致商機的流失和產業發展速度的放緩。

こうした規制上の遅延による影響は、迅速かつ効果的な治療を必要とする重大な疾病負担によってさらに深刻化しています。米国甲状腺協会（ATA）の推計によれば、2025年には約2,000万人のアメリカ人が何らかの甲状腺疾患に苦しむ見込みです。この膨大な患者数は、先進治療方法の緊急性に対する需要と、產品核可の遅々たる進捗との乖離を浮き彫りにしています。新規治療方法の迅速な市場参入を阻む規制上の障壁は、この広範な患者層のニーズに対応する業界の能力を制限し、ひいては市場全体の拡大を妨げています。

市場趨勢

AI駆動型診断,モニタリングソリューションの統合は、画像診断の精度とワークフロー効率を向上させることで、甲状腺結節の臨床管理に革命をもたらしています。メーカー各社は、放射線科医が甲状腺病変の一貫した検出、セグメンテーション、分類を支援するため、超音波システムへの深層学習アルゴリズムの積極的な組み込みを進めています。この技術的進化は、手動検査にありがちな主観性を軽減し、リスク評価通訊協定を標準化することで、良性結節に対する不必要な切片檢查率の低減が期待されます。例えば、サムスンメディソンが2025年11月に発表した新型超音波診斷設備「R20」のプレスリリースでは、測定の自動化や複雑な症例に対するリアルタイム診断ガイダンスを提供する10以上のAIツールを搭載している点が強調されています。

同時，針對蛋白酪氨酸激酶抑制劑在甲狀腺癌治療中的廣泛應用，正在重新定義放射性碘抗藥性患者的治療選擇。隨著我們對甲狀腺惡性腫瘤分子機制的認知不斷加深，精準腫瘤療法（例如抑制VEGFR和RET等特定路徑）的應用顯著增加。這種向分子標靶療法的轉變，正大幅提升製藥公司的收入，因為口服藥物正逐漸成為傳統化療的標準替代方案。 2025年5月，Exelisys公司公佈其旗艦蛋白酪氨酸激酶抑制劑Cabometyx第一季淨銷售額達5.133億美元，主要得益於包括分化型甲狀腺癌在內的所有腫瘤適應症需求的成長。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球甲狀腺疾病治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 適應症（甲狀腺機能低下症、甲狀腺功能亢進）
    • 給藥途徑（口服、靜脈注射、其他）
    • 分銷通路細分（批發商/經銷商、零售連鎖店、線上分銷、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美甲狀腺疾病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲甲狀腺疾病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區甲狀腺疾病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲甲狀腺疾病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲甲狀腺疾病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球甲狀腺疾病治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Abbvie Inc.
  • Amgen Inc.
  • GSK Plc
  • Merck KGaA
  • Viatris Inc.
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Elexis Inc.
  • IBSA Group

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 18994

The Global Thyroid Gland Disorder Treatment Market is projected to expand from USD 2.93 Billion in 2025 to USD 3.77 Billion by 2031, registering a CAGR of 4.29%. This market includes various pharmaceutical interventions and therapies, including levothyroxine and radioactive iodine, designed to restore hormonal equilibrium in individuals suffering from hypothyroidism, hyperthyroidism, or thyroid cancer. Growth is largely propelled by the rising global incidence of thyroid dysfunction and an aging demographic requiring long-term disease management. For instance, the American Cancer Society estimates that roughly 44,020 new thyroid cancer cases will arise in the United States in 2025. This significant patient load highlights the urgent necessity for a reliable supply of therapeutics and stimulates demand for effective treatment solutions within international healthcare systems.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.93 Billion
Market Size 2031USD 3.77 Billion
CAGR 2026-20314.29%
Fastest Growing SegmentOral
Largest MarketNorth America

However, the sector encounters substantial hurdles due to the strict regulatory frameworks governing the approval of new treatments. Rigorous compliance requirements and comprehensive safety validations for new drug formulations frequently prolong development schedules and escalate operational expenses. These regulatory obstacles effectively retard the pace at which innovative therapies reach the commercial market, potentially hindering expansion in emerging economies that are still developing their healthcare infrastructure.

Market Driver

The rising global prevalence of thyroid disorders serves as a major driver for market growth, creating a critical need for a reliable supply of hormone replacement therapies. With hypothyroidism rates increasing due to aging demographics and enhanced diagnostic capabilities, reliance on standard treatments such as levothyroxine is intensifying. This consistent patient demand generates substantial commercial volume for established pharmaceutical companies, securing steady revenue within the chronic care sector. For example, Merck Group's November 2025 report indicated that its primary thyroid medication, Euthyrox, achieved 9.6% organic net sales growth driven by robust global demand. Furthermore, an August 2025 press release from the U.S. Food and Drug Administration noted that approximately 22 million patients in the United States were prescribed levothyroxine in 2024, evidencing the heavy disease burden.

Concurrently, the uptake of novel drug formulations is broadening revenue sources beyond traditional generic hormone replacements. Pharmaceutical companies are actively investing in biologics and targeted therapies to manage complex conditions like Thyroid Eye Disease (TED) and refractory thyroid cancers. These innovations provide high-value alternatives to conventional therapies, gaining market share through better clinical results and premium pricing. Amgen Inc., in its third-quarter 2025 financial results, reported that global sales of Tepezza, a targeted treatment for thyroid eye disease, rose by 15% year-over-year to $560 million. This increase in adoption highlights a significant industry shift toward specialized treatments designed to meet specific, unaddressed needs across the thyroid disorder landscape.

Market Challenge

Stringent regulatory frameworks represent a major obstacle to the growth of the Global Thyroid Gland Disorder Treatment Market. Developers are required to navigate intricate compliance protocols and execute comprehensive clinical trials to confirm the safety and efficacy of new treatments. These rigorous demands substantially increase operational expenses and prolong development cycles, resulting in bottlenecks that delay the commercial introduction of innovative drug formulations. As a result, the market struggles to adapt quickly to the changing requirements of healthcare providers and patients, which leads to lost revenue potential and decelerated industry advancement.

The consequences of these regulatory delays are exacerbated by the significant disease burden necessitating prompt and effective care. The American Thyroid Association estimates that in 2025, around 20 million Americans suffer from some type of thyroid condition. This immense patient volume underscores the disparity between the urgent need for advanced therapies and the sluggish pace of product approvals. By hindering the rapid market entry of new treatments, regulatory barriers restrict the industry's capacity to address the needs of this extensive patient population, thereby impeding overall market expansion.

Market Trends

The integration of AI-driven diagnostic and monitoring solutions is revolutionizing the clinical management of thyroid nodules by improving imaging precision and workflow efficiency. Manufacturers are actively incorporating deep learning algorithms into ultrasound systems to aid radiologists in the consistent detection, segmentation, and classification of thyroid lesions. This technological evolution mitigates the subjectivity common in manual examinations, standardizing risk assessment protocols and potentially lowering the rate of unnecessary biopsies for benign nodules. For instance, Samsung Medison's November 2025 press release regarding its new R20 ultrasound system highlights the inclusion of over a dozen AI tools designed to automate measurements and offer real-time diagnostic guidance for complex cases.

Simultaneously, the proliferation of targeted tyrosine kinase inhibitors for thyroid cancer is redefining treatment options for patients with radioactive iodine-refractory disease. As knowledge regarding the molecular causes of thyroid malignancy expands, there is a marked increase in the adoption of precision oncology therapies that block specific pathways like VEGFR and RET. This transition towards molecularly targeted treatments is fueling significant revenue growth for pharmaceutical companies, as these oral medications emerge as standard alternatives to traditional chemotherapy. Exelixis Inc. reported in May 2025 that its flagship tyrosine kinase inhibitor, Cabometyx, achieved net product revenues of $513.3 million for the first quarter, driven by rising demand across oncology indications, including differentiated thyroid cancer.

Key Market Players

  • Abbvie Inc.
  • Amgen Inc.
  • GSK Plc
  • Merck KGaA
  • Viatris Inc.
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Elexis Inc.
  • IBSA Group

Report Scope

In this report, the Global Thyroid Gland Disorder Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Thyroid Gland Disorder Treatment Market, By Indication

  • Hypothyroidism
  • Hyperthyroidism

Thyroid Gland Disorder Treatment Market, By Route of Administration

  • Oral
  • Intravenous
  • Others

Thyroid Gland Disorder Treatment Market, By Distribution Channel

  • Wholesaler/Distributors
  • Retail Chain
  • Online Distribution
  • Others

Thyroid Gland Disorder Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Thyroid Gland Disorder Treatment Market.

Available Customizations:

Global Thyroid Gland Disorder Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Thyroid Gland Disorder Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Hypothyroidism, Hyperthyroidism)
    • 5.2.2. By Route of Administration (Oral, Intravenous, Others)
    • 5.2.3. By Distribution Channel (Wholesaler/Distributors, Retail Chain, Online Distribution, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Thyroid Gland Disorder Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Route of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Thyroid Gland Disorder Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Thyroid Gland Disorder Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Thyroid Gland Disorder Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Distribution Channel

7. Europe Thyroid Gland Disorder Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Thyroid Gland Disorder Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Thyroid Gland Disorder Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Thyroid Gland Disorder Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Thyroid Gland Disorder Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Thyroid Gland Disorder Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Thyroid Gland Disorder Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Thyroid Gland Disorder Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Thyroid Gland Disorder Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Thyroid Gland Disorder Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Thyroid Gland Disorder Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Thyroid Gland Disorder Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Thyroid Gland Disorder Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Thyroid Gland Disorder Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Thyroid Gland Disorder Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Thyroid Gland Disorder Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel

10. South America Thyroid Gland Disorder Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Thyroid Gland Disorder Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Thyroid Gland Disorder Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Thyroid Gland Disorder Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Thyroid Gland Disorder Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbvie Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Amgen Inc.
  • 15.3. GSK Plc
  • 15.4. Merck KGaA
  • 15.5. Viatris Inc.
  • 15.6. Novartis AG
  • 15.7. Pfizer Inc.
  • 15.8. Takeda Pharmaceutical Company Limited
  • 15.9. Elexis Inc.
  • 15.10. IBSA Group

16. Strategic Recommendations

17. About Us & Disclaimer